1yr
Breast Cancer Connect
1yr
1yr
Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review)
Source : https://pubmed.ncbi.nlm.nih.gov/38456493/
Breast cancer arises from the malignant transformation of mammary epithelial cells under the influence of various carcinogenic factors, leading to a gradual increase in its prevalence. This disease has become...
The review explores cuproptosis, ferroptosis, and pyroptosis in breast cancer, examining their roles in disease progression and drug efficacy, offering insights for novel treatments and research.
1yr
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Source : https://pubmed.ncbi.nlm.nih.gov/38300710/
BACKGROUNDHER2-targeting therapies have great efficacy in HER2-positive breast cancer, but resistance, in part due to HER2 heterogeneity (HET), is a significant clinical challenge. We previously described that in a phase...
HER2-targeting therapy efficacy is reduced in HER2 heterogeneity (HET) tumors, which show distinct resistance mechanisms. Stratification and downstream ERBB pathway targeting are recommended for HET tumors.
2yr
Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond
Source : https://pubmed.ncbi.nlm.nih.gov/38339330/
Among neoplastic diseases, breast cancer (BC) is one of the most influenced by gender. Despite common misconceptions associating BC as a women-only disease, BC can also occur in men. Additionally,...
Understanding gender-specific genetic factors in breast cancer is crucial for personalized risk assessment and treatment. Distinguishing male and female BC genetics enhances precision in prevention and care strategies.